Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphine + remifentanil is a combination of two opioid analgesics used together primarily in anesthesia and perioperative pain management. Morphine is a naturally occurring opioid that acts as an agonist at the mu-opioid receptor, providing potent analgesia and sedation. Remifentanil is a synthetic, ultra-short-acting opioid also acting as a selective mu-opioid receptor agonist, notable for its rapid onset and offset due to metabolism by nonspecific blood and tissue esterases. The combination may be used to enhance intraoperative or postoperative pain control, particularly in settings such as cardiac surgery or intensive care where rapid titration of analgesia is required[4][5]. Both drugs act synergistically on the central nervous system to provide profound analgesia but require careful monitoring due to risks of respiratory depression and other opioid-related adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine + remifentanil.